SHSE:688091 (China)
Â
Class A
Â¥
41.41
-0.24 (-0.58%)
Sep 22
Business Description
Shanghai Yizhong Pharmaceutical Co Ltd
SIC : 2834
ISIN : CNE1000050F4
Share Class Description:
SHSE:688091: Class ATotal Employee Number:
437Compare
Compare
Traded in other countries / regions
688091.China Index Membership
SSE Composite Index IPO Date
2021-09-09Description
Shanghai Yizhong Pharmaceutical Co Ltd is a China-based pharmaceutical company focused on oncology and related therapeutic areas. It researches, develops, manufactures, and sells anti-tumor drugs, with particular emphasis on novel drug delivery formulations and improved dosage forms of established cancer therapies. Its product portfolio centers on injectable and oral oncology treatments, including reformulated generic and improved drugs, and the company also provides contract development and manufacturing services for pharmaceutical partners. Revenue is generated primarily through the sale of its own pharmaceutical products to hospitals and medical institutions across China, supplemented by technology licensing and CDMO arrangements. The company operates manufacturing facilities in Shanghai and invests significantly in research and development to expand its pipeline of anti-cancer candidates. Its customers are mainly domestic hospitals, distributors, and pharmaceutical companies, with its commercial activity concentrated in the Chinese market.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 17.63 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.4 | |||||
Interest Coverage | 162.08 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 42.63 | |||||
Beneish M-Score | -2.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.6 | |||||
3-Year EBITDA Growth Rate | -24.2 | |||||
3-Year EPS without NRI Growth Rate | -15.5 | |||||
3-Year Book Growth Rate | 2.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.53 | |||||
9-Day RSI | 52.71 | |||||
14-Day RSI | 50.6 | |||||
3-1 Month Momentum % | 1.1 | |||||
6-1 Month Momentum % | -25.66 | |||||
12-1 Month Momentum % | -28.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.84 | |||||
Quick Ratio | 13.22 | |||||
Cash Ratio | 5.25 | |||||
Days Inventory | 422.95 | |||||
Days Sales Outstanding | 120.87 | |||||
Days Payable | 354.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | -0.18 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 84.47 | |||||
Operating Margin % | 14.82 | |||||
Net Margin % | 21.41 | |||||
EBITDA Margin % | 19.47 | |||||
FCF Margin % | -6.72 | |||||
OCF Margin % | 17.03 | |||||
ROE % | 4.73 | |||||
ROA % | 4.46 | |||||
ROIC % | 4.68 | |||||
3-Year ROIIC % | -8.7 | |||||
ROC (Joel Greenblatt) % | 12.99 | |||||
ROCE % | 4.25 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 123.24 | |||||
PE Ratio without NRI | 124.73 | |||||
Price-to-Owner-Earnings | 505.01 | |||||
PS Ratio | 25.88 | |||||
PB Ratio | 5.74 | |||||
Price-to-Tangible-Book | 5.86 | |||||
Price-to-Operating-Cash-Flow | 174.72 | |||||
EV-to-EBIT | 130.23 | |||||
EV-to-EBITDA | 103.94 | |||||
EV-to-Revenue | 25.32 | |||||
EV-to-FCF | -376.95 | |||||
Price-to-GF-Value | 0.88 | |||||
Price-to-Projected-FCF | 8.66 | |||||
Price-to-Graham-Number | 5.58 | |||||
| Price-to-Net-Current-Asset-Value | 8.2 | |||||
| Price-to-Net-Cash | 26.3 | |||||
Earnings Yield (Greenblatt) % | 0.77 | |||||
FCF Yield % | -0.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Yizhong Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 321.605 | ||
| EPS (TTM) (Â¥) | 0.336 | ||
| Beta | 1.4556 | ||
| 3-Year Sharpe Ratio | 0.06 | ||
| 3-Year Sortino Ratio | 0.11 | ||
| Volatility % | 37.74 | ||
| 14-Day RSI | 50.6 | ||
| 14-Day ATR (Â¥) | 1.802569 | ||
| 20-Day SMA (Â¥) | 39.3995 | ||
| 12-1 Month Momentum % | -28.7 | ||
| 52-Week Range (Â¥) | 35.28 - 66.2 | ||
| Shares Outstanding (Mil) | 206.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Yizhong Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Yizhong Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| 1.3:1 Stock Split | 2024-05-17 | 28.97 (-3.14%) | ||
| 1.1:1 Stock Split | 2023-04-20 | 68.06 (+0.16%) | ||
| 1.36:1 Stock Split | 2022-10-20 | 54.96 (+5.31%) |
Show
Entries
Shanghai Yizhong Pharmaceutical Co Ltd Frequently Asked Questions
What is Shanghai Yizhong Pharmaceutical Co Ltd(SHSE:688091)'s stock price today?
The current price of SHSE:688091 is ¥41.41. The 52 week high of SHSE:688091 is ¥66.20 and 52 week low is ¥35.28.
When is next earnings date of Shanghai Yizhong Pharmaceutical Co Ltd(SHSE:688091)?
The next earnings date of Shanghai Yizhong Pharmaceutical Co Ltd(SHSE:688091) is .
Does Shanghai Yizhong Pharmaceutical Co Ltd(SHSE:688091) pay dividends? If so, how much?
Shanghai Yizhong Pharmaceutical Co Ltd(SHSE:688091) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers